Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
about
Proteomics investigations of HDL: challenges and promiseRegression of atherosclerosis: insights from animal and clinical studiesCrystal Structures of Cholesteryl Ester Transfer Protein in Complex with InhibitorsNew Era of Lipid-Lowering DrugsWill Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivoAnacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk ReductionDalcetrapib: a review of Phase II data.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementCholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical OutcomesABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet.eNOS activation by HDL is impaired in genetic CETP deficiency.Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.Future therapeutic directions in reverse cholesterol transport.Novel HDL-directed pharmacotherapeutic strategies.Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.High-Density Lipoprotein - A Hero, a Mirage, or a Witness?Novel biological functions of high-density lipoprotein cholesterolTreatment with the herbal medicine, naoxintong improves the protective effect of high-density lipoproteins on endothelial function in patients with type 2 diabetes.ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase.Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?Anacetrapib: hope for CETP inhibitors?Applications of 'decisionable' biomarkers in cardiovascular drug development.CETP Inhibition: does the future look promising?Apo a-I modulating therapies.Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.Rationale for cholesteryl ester transfer protein inhibition.An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development.High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.Role of HDL in those with diabetes.
P2860
Q27000995-1534678E-5F59-4CD3-BB62-71E89114C653Q27028112-BB9E07C5-BE0E-4ADE-B70E-44AD26A7A3A7Q27672820-62994273-584E-4D65-982D-5029E3ECFE9DQ28072298-A69E666F-F504-4A79-BC91-39682F2CFEE4Q28080768-E6DD8054-664E-4049-898F-9103B298CF9BQ28086787-4215E84D-A464-4491-B40B-80F16A8E4B84Q28508467-F083CFFB-7C8B-4C02-81EE-260BE0FC78B5Q29999973-8F64602D-30EC-49DC-A19D-263F6A26868EQ33577236-35370098-2109-4ECC-990A-05F5C365F8F8Q33590777-8B2F4798-654D-4562-A079-AD46C940EBBBQ33993233-9F309C57-87A4-4CD3-9EBD-7FE86C544754Q34021570-362F1C62-426F-45EC-8393-3B99CCBAF5B7Q34181381-EE407C42-43F7-4926-AF97-075D88617DA8Q34253290-6EFC2E62-3246-4E33-ABC8-32C20996B4ACQ34534212-B9B0C32C-DF4A-42BC-91A1-8CD8E481865FQ34657417-5BEDB8A6-C28C-46FE-ABAA-54199C048E36Q35168995-842BB747-2A1A-4F93-ACB3-1398C0170334Q35747803-F8AB3620-2477-40D3-B84C-29E0F8B25038Q35860010-07EF70BA-254B-45B4-87EE-D5895FD87300Q35860020-6B2DFC4D-9FF5-48F1-BD7C-DF9E1C351A65Q35860029-9FDF7689-0E6F-4EB6-9236-D99F29089AB4Q36344712-7F0EE81B-37C2-43F5-B798-3E34CB41CE25Q36406480-078F38EF-5FFD-49D4-86A4-A04CAD2EFE37Q36623865-E796E693-5770-423B-8E80-5771086908A1Q36682924-C235749A-652C-4C97-8C0B-F60019615058Q37146755-1A09C5C5-016B-4F43-8CC4-DC5B1565EF52Q37606964-DD75243B-7AAB-46BF-B1E4-597ECDD77EA1Q37707402-2E4DDB37-6BB8-4819-AD47-420F7251A614Q37734553-5E099BDC-97C7-468E-B447-9747236C129BQ37816414-4FA5442D-B4B7-418A-8F24-74964C2BAFE2Q37930463-50E80D35-2A64-45AB-8397-C83320C0911BQ37938833-5797DFDB-4F69-4638-A906-F0A0C088222BQ37941053-11812B2B-986B-45F8-A5C0-EB47C66509C5Q37987207-9EED81E1-14AD-4E0C-8E40-A8D36D4B4995Q38003957-34944465-6923-4871-AE68-5DD47BBEA3F2Q38032616-BB2D396F-2689-47E0-AAEC-77CEA62DD08EQ38048831-91BC47B7-4DC0-43EF-AAD3-1A4989767B2BQ38089207-9220B2EF-FB50-4A9D-9AC6-9F09BCCE3024Q38203096-95B56E66-E0DB-4E02-B766-E2C51C22D8A7Q38221965-5B026B31-EBB3-412E-86E8-B8763DA7A514
P2860
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Inhibition of cholesteryl este ...... age cholesterol efflux to HDL.
@en
Inhibition of cholesteryl este ...... age cholesterol efflux to HDL.
@nl
type
label
Inhibition of cholesteryl este ...... age cholesterol efflux to HDL.
@en
Inhibition of cholesteryl este ...... age cholesterol efflux to HDL.
@nl
prefLabel
Inhibition of cholesteryl este ...... age cholesterol efflux to HDL.
@en
Inhibition of cholesteryl este ...... age cholesterol efflux to HDL.
@nl
P2093
P1476
Inhibition of cholesteryl este ...... age cholesterol efflux to HDL.
@en
P2093
Alan R Tall
Charles L Shear
Franz Rinninger
Fumihiko Matsuura
Mark J Bamberger
Xian-Cheng Jiang
P304
P356
10.1161/ATVBAHA.106.138347
P407
P577
2007-02-22T00:00:00Z